Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase I/II, multicenter, open-label, multi-arm study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of idasanutlin, administered as a single agent or in combination with chemotherapy or venetoclax, in pediatric and young adult participants with acute leukemias or solid tumors.
This study is divided into three parts: Part 1 will begin with dose escalation of idasanutlin as a single agent in pediatric participants with relapsed or refractory solid tumors to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and to characterize dose-limiting toxicities (DLTs). Following MTD/MAD identification, three separate safety run-in cohorts in neuroblastoma, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) will be conducted to identify the recommended Phase 2 dose (RP2D) of idasanutlin in each combination, with chemotherapy or venetoclax. Part 2 will evaluate the safety and early efficacy of idasanutlin in combination with chemotherapy or venetoclax in newly enrolled pediatric and young adult participants in neuroblastoma, AML,and ALL cohorts at idasanutlin RP2D. Part 3 will potentially be conducted as an additional expansion phase of the idasanutlin combination cohorts in neuroblastoma, AML, or ALL for further response and safety assessment.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Additional Inclusion Criteria for Participants with Solid Tumors (including Neuroblastoma)
Additional Inclusion Criteria for Patients with Leukemia
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
38 participants in 6 patient groups
Loading...
Central trial contact
Reference Study ID Number: GO40871 https://forpatients.roche.com/
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal